Morinamide is a second line anti-tuberculous agent. In vitro morinamide demonstrated clear dose-dependent bacteriostatic and bactericidal activities. The anti-mycobacterial effect of morinamide was the same as pyrazinamide and was dependent on the acidity of medium (pH 5.6). Liver function test abnormalities following morinamide therapy are usually mild, and onset of jaundice is extremely uncommon. It has been given orally as the hydrochloride in the treatment of tuberculosis.